# Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting

> **NCT06324734** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2506 (actual)

## Conditions studied

- Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06324734
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-29
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 2506 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06324734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06324734, "Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06324734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*